NL8000768A - Een acyl-carnitine bevattend farmaceutisch preparaat. - Google Patents

Een acyl-carnitine bevattend farmaceutisch preparaat. Download PDF

Info

Publication number
NL8000768A
NL8000768A NL8000768A NL8000768A NL8000768A NL 8000768 A NL8000768 A NL 8000768A NL 8000768 A NL8000768 A NL 8000768A NL 8000768 A NL8000768 A NL 8000768A NL 8000768 A NL8000768 A NL 8000768A
Authority
NL
Netherlands
Prior art keywords
cerebral
formula
acyl
carnitine
acetyl
Prior art date
Application number
NL8000768A
Other languages
English (en)
Dutch (nl)
Original Assignee
Cavazza Claudio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT7947976A external-priority patent/IT1206954B/it
Priority claimed from IT50795/79A external-priority patent/IT1164062B/it
Application filed by Cavazza Claudio filed Critical Cavazza Claudio
Publication of NL8000768A publication Critical patent/NL8000768A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL8000768A 1979-02-12 1980-02-07 Een acyl-carnitine bevattend farmaceutisch preparaat. NL8000768A (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT7947976A IT1206954B (it) 1979-02-12 1979-02-12 Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT4797679 1979-02-12
IT50795/79A IT1164062B (it) 1979-11-09 1979-11-09 Composizione farmaceutica comprendente una acil-carnitina per il trattamento del rallentato metabolismo cerebrale
IT5079579 1979-11-09

Publications (1)

Publication Number Publication Date
NL8000768A true NL8000768A (nl) 1980-08-14

Family

ID=26329263

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8000768A NL8000768A (nl) 1979-02-12 1980-02-07 Een acyl-carnitine bevattend farmaceutisch preparaat.

Country Status (8)

Country Link
US (1) US4346107A (xx)
AU (1) AU535518B2 (xx)
BE (1) BE881680A (xx)
CH (1) CH641673A5 (xx)
DE (1) DE3005208A1 (xx)
FR (1) FR2448348A1 (xx)
GB (1) GB2046593A (xx)
NL (1) NL8000768A (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198434B (it) * 1981-01-06 1988-12-21 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
IT1284650B1 (it) * 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
AU749638B2 (en) * 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) * 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5869528A (en) * 1997-07-22 1999-02-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutical method for the treatment of attention-deficit/hyperactive disorders
IT1299195B1 (it) * 1998-06-25 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
DE60138019D1 (de) * 2000-05-01 2009-04-30 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
CA2448246A1 (en) * 2001-05-29 2002-12-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
US20100010336A1 (en) * 2002-02-07 2010-01-14 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including attention deficit hyperactivity disorder (adhd), autism, and schizophrenia
KR20040083471A (ko) * 2002-02-07 2004-10-02 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 노인성 우울증의 치료에서 카르니틴의 용도
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US8894973B2 (en) * 2002-02-07 2014-11-25 Jay W. Pettegrew Method and system for differential diagnosis of chronic schizophrenia and chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
EP1641806B1 (en) * 2003-05-29 2009-07-29 Jay W. Pettegrew Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
WO2006020137A2 (en) 2004-07-16 2006-02-23 Ketocytonyx Inc. Oligomeric compounds
EP1778615A4 (en) * 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
EP1778212A4 (en) * 2004-07-23 2010-12-08 Btg Int Ltd SACCHARIDES CETOGENES
EP1793813A4 (en) * 2004-09-21 2011-05-18 Btg Int Ltd TREATMENT OF HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION (ADHD)
ES2574557T3 (es) * 2004-09-21 2016-06-20 Btg International Limited Miméticos dopaminérgicos
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
EP2001293B9 (en) * 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
EP2650381B1 (en) 2007-07-31 2016-09-21 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
CN102105071A (zh) * 2008-07-03 2011-06-22 艾克塞拉公司 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
SG10201503032UA (en) * 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
AU2021272292A1 (en) 2020-05-15 2023-02-02 Alfasigma S.P.A. Composition comprising methylfolate
IT202100020729A1 (it) 2021-08-02 2023-02-02 Univ Degli Studi Di Napoli Federico Ii Preparazione combinata per il trattamento della malattia di Pompe

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE700864A (xx) * 1967-07-03 1967-12-18
GB1256162A (en) * 1968-08-16 1971-12-08 Braun Fa B Improvements in and relating to liquid products for intravenous administration
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
JPS531812B2 (xx) * 1972-12-07 1978-01-23
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
IT1143611B (it) * 1977-11-03 1986-10-22 Sigma Tau Ind Farmaceuti Applicazione della acetil-carnitina nella terapia delle affezioni cardiache di/tipo anossico,ischemico,cardiotossico e nelle sindromi aritmiche
FR2414914A1 (fr) * 1978-01-18 1979-08-17 Sigma Tau Ind Farmaceuti Utilisations therapeutiques nouvelles de l'acetyl-1-carnitine et d'autres derives acyles de la 1-carnitine
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi

Also Published As

Publication number Publication date
CH641673A5 (it) 1984-03-15
GB2046593A (en) 1980-11-19
FR2448348A1 (fr) 1980-09-05
BE881680A (fr) 1980-05-30
AU5526780A (en) 1980-08-21
US4346107A (en) 1982-08-24
DE3005208C2 (xx) 1989-12-28
AU535518B2 (en) 1984-03-29
DE3005208A1 (de) 1980-08-21

Similar Documents

Publication Publication Date Title
NL8000768A (nl) Een acyl-carnitine bevattend farmaceutisch preparaat.
JPH0233014B2 (xx)
DE69937198T2 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
Gillin et al. The cholinergic rapid eye movement induction test with arecoline in depression
JP4151853B2 (ja) エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤
US20090137565A1 (en) Method for treatment of movement disorders
US5192805A (en) Use of acetyl l-carnitine in the therapeutic treatment of coma
Hakkarainen et al. Piracetam in the treatment of post-concussional syndrome
JPH08231391A (ja) 痴呆症状改善薬
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
Betts Epilepsy and stress.
Gillin et al. Rapid Eye Movement (REM) sleep: cholinergic mechanisms1
US4626527A (en) Process for utilizing choline to sustain muscular performance
DE60217653T2 (de) Verwendung von Melatonin zur Behandlung von Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom
DE60306503T2 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
EP1909793A2 (de) Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben
CA2217463C (fr) Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels
Botter A clinical double-blind comparison of maprotiline and amitriptvline in depression
US8013016B2 (en) Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
RU2127589C1 (ru) Способ лечения стрессорных поражений нервной системы
Tarakanov et al. Universal mechanisms of SCENAR-effect in oxidative stress
JPH09132553A (ja) ドーパミンまたはＬ−ドーパのｎ−３系不飽和脂肪酸誘導体
AU3011300A (en) Agent for enhancing cerebral acetylcholine release
MXPA97007269A (en) A method of treatment of mania and disorderbipo

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed